Replimune Group (REPL) shares were down nearly 64% in premarket activity Monday. On Friday, the US Food and Drug Administration said it rejected the company's biologics license application for vusolimogene oderparepvec. Also, multiple analysts downgraded their ratings on Replimune's stock.
Strive Asset Management (ASST) stock was down 4.7% pre-bell, paring Friday's rally.
Best Buy (BBY) stock was 4.5% lower after Goldman Sachs downgraded the company to sell from buy and lowered its price target to $59 from $76.
Petco Health & Wellness (WOOF) shares were down 2.5% after Goldman Sachs downgraded the company to neutral from buy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments